http://repositorio.unb.br/handle/10482/42137
Fichier | Description | Taille | Format | |
---|---|---|---|---|
ARTIGO_CommentaryMesenchymalStemCells.pdf | 240,82 kB | Adobe PDF | Voir/Ouvrir |
Titre: | Commentary : mesenchymal stem cells : a new piece in the puzzle of COVID-19 treatment |
Auteur(s): | Carvalho, Juliana Lott de Melgaço Garcez, Emãnuella Carvalho, Amandda Évelin Silva de Araujo, Felipe Saldanha de |
Assunto:: | Covid-19 Células-tronco mesenquimais Terapia com células-tronco SARS-CoV-2 |
Date de publication: | 29-avr-2021 |
Editeur: | Frontiers Media |
Référence bibliographique: | CARVALHO, Juliana Lott et al. Commentary: mesenchymal stem cells: a new piece in the puzzle of COVID-19 treatment. Frontiers in Immunology, 29 abr. 2021. DOI: https://doi.org/10.3389/fimmu.2021.682195. Disponível em: https://www.frontiersin.org/articles/10.3389/fimmu.2021.682195/full. Acesso em: 14 out. 2021. |
metadata.dc.description.unidade: | Faculdade de Medicina (FMD) |
Description: | A Commentary on Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment By Saldanha-Araujo F, Melgaço Garcez E, Silva-Carvalho AE and Carvalho JL (2020). Front. Immunol. 11:1563. doi: 10.3389/fimmu.2020.01563. |
Licença:: | Copyright © 2021 Carvalho, Silva-Carvalho, Garcez and Saldanha-Araujo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
DOI: | https://doi.org/10.3389/fimmu.2021.682195 |
metadata.dc.relation.isbasedon: | https://repositorio.unb.br/handle/10482/39544 |
Collection(s) : | Artigos publicados em periódicos e afins UnB - Covid-19 |
Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.